Biogen Idec execs credit bolstered sales forces in Tysabri uptick
Ben Comer
October 28 2010
Biogen Idec and Elan's MS drug Tysabri realized a 15% increase in US revenues during the third quarter (compared with ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Your message:
The e-mail address(es) that you supply to use this service will only be used to send the requested article.